Successive clinical trials with tofersen in patients with SOD1-ALS found a significant decrease in SOD1 peptide levels together with those of Nfl, but the phase 3 clinical trial did not meet the primary endpoint [33], as was discussed in the Neurofilament Section. Here, SOD1 is linked to amyotrophic lateral sclerosis.